[How to convince the head of department and managing director of the importance of specialised headache clinics]

Rev Neurol. 2015:61 Suppl 1:S13-20.
[Article in Spanish]

Abstract

In spite that headache is, by far, the most frequent reason for neurological consultation and that the diagnosis and treatment of some patients with headache is difficult, the number of headache clinics is scarce in our country. In this paper the main arguments which should allow us, as neurologists, to defend the necessity of implementing headache clinics are reviewed. To get this aim we should first overcome our internal reluctances, which still make headache as scarcely appreciated within our specialty. The facts that more than a quarter of consultations to our Neurology Services are due to headache, that there are more than 200 different headaches, some of them actually invalidating, and the new therapeutic options for chronic patients, such as OnabotulinumtoxinA or neuromodulation techniques, oblige us to introduce specialised headache attendance in our current neurological offer. Even though there are no definite data, available results indicate that headache clinics are efficient in patients with chronic headaches, not only in terms of health benefit but also from an economical point of view.

Title: Como convencer al jefe de servicio y al gerente de la importancia de las unidades/consultas especializadas de cefaleas.

A pesar de que la cefalea es, con diferencia, el principal motivo neurologico de consulta, y de la complejidad diagnostica y terapeutica de algunos pacientes, el numero de consultas monograficas de cefalea (CC) y de unidades de cefalea (UC) es muy reducido en nuestro pais. En este articulo pasaremos revista a los principales argumentos que nos permitan, como neurologos, defender la necesidad de la implementacion de una CC/UC, dependiendo de la poblacion que se debe atender, en todos nuestros servicios de neurologia. Para ello deberemos, en primer lugar, vencer las reticencias internas, que hacen que la cefalea sea aun poco apreciada y atractiva dentro de nuestra especialidad. El hecho de que la cefalea justifique mas de un cuarto de las consultas a un servicio de neurologia estandar de nuestro pais y de que existan mas de 200 cefaleas diferentes, algunas de ellas realmente invalidantes, y las nuevas opciones de tratamiento para pacientes cronicos, como la OnabotulinumtoxinA para la migraña cronica o las tecnicas de neuromodulacion, obligan a introducir dentro de nuestras carteras de servicios la asistencia especializada en cefaleas. Aunque no disponemos de datos incontrovertibles, existen ya datos suficientes en la literatura que indican que esta atencion es eficiente en pacientes con cefaleas cronicas no solo en terminos de salud, sino tambien desde el punto de vista economico.

MeSH terms

  • Acetylcholine Release Inhibitors / economics
  • Acetylcholine Release Inhibitors / therapeutic use
  • Analgesics / economics
  • Analgesics / therapeutic use
  • Attitude of Health Personnel*
  • Botulinum Toxins, Type A / economics
  • Botulinum Toxins, Type A / therapeutic use
  • Cost Savings
  • Drug Utilization
  • Efficiency, Organizational
  • Electric Stimulation Therapy / economics
  • Headache / economics
  • Headache / epidemiology
  • Headache / therapy*
  • Health Services Needs and Demand
  • Hospital Administrators / psychology
  • Hospital Departments / organization & administration
  • Hospital Units* / economics
  • Hospital Units* / organization & administration
  • Hospital Units* / supply & distribution
  • Humans
  • Migraine Disorders / drug therapy
  • Migraine Disorders / economics
  • Migraine Disorders / therapy
  • Nerve Block / economics
  • Neurology / economics
  • Neurology / organization & administration*
  • Outpatient Clinics, Hospital* / economics
  • Outpatient Clinics, Hospital* / organization & administration
  • Outpatient Clinics, Hospital* / supply & distribution
  • Persuasive Communication*
  • Physicians / psychology
  • Prevalence
  • Therapies, Investigational / economics

Substances

  • Acetylcholine Release Inhibitors
  • Analgesics
  • Botulinum Toxins, Type A